MB-106 / Fortress, Fred Hutchinson Cancer Center - LARVOL DELTA

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial (ASH 2023) - "Following lymphodepletion (cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day for 3 days), MB-106 is administered to patients with indolent B-cell NHL at one of two dose levels (DL): DL1, 3.3×106; and DL2, 1.0×107 cells/kg. Treatment with MB-106, a third generation CD20 targeting CAR-T, resulted in responses, including CRs, and CAR-T persistence in patients with R/R indolent NHL and was associated with favorable safety profile with no occurrence of Grade 3 or Grade 4 cytokine release syndrome and no ICANS of any grade. CRs have been observed in patients previously treated with CD19-targeted CAR-T in both this multicenter trial and the original single institution trial. Dosing is ongoing in the final dosing level (1.0×107 cells/kg) to establish the recommended Phase 2 dose for a planned pivotal trial in WM."

Clinical • IO biomarker • P1 data • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hairy Cell Leukemia • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia • CD20

MB106-CD20-001: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (clinicaltrials.gov) - P1/2 | N=20 | Terminated | Sponsor: Mustang Bio | N=287 ➔ 20 | Trial completion date: Sep 2026 ➔ Apr 2024 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2026 ➔ Apr 2024; Business reasons

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia • BCL2 • BCL6 • CD20

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (clinicaltrials.gov) - P=N/A | N=3 | Terminated | Sponsor: Mustang Bio | N=331 ➔ 3 | Trial completion date: Jul 2041 ➔ Apr 2024 | Enrolling by invitation ➔ Terminated | Trial primary completion date: Apr 2041 ➔ Apr 2024; Business Reasons

CAR T-Cell Therapy • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hairy Cell Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia

HIGH EFFICACY AND FAVORABLE SAFETY OF CD20-TARGETED CAR-T THERAPY FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) (EHA 2024) - "Lymphodepletion (LD) consisted of cyclophosphamide +fludarabine...All 10 pts had BTKi refractory disease (9 ibrutinib, 2 acalabrutinib, 5zanubrutinib, 1 pirtobrutinib)...Bridgingtherapy was continuation of BTKi (n=5), bendamustine (n=1), dexamethasone (n=1), or none (n=3). Of 8evaluable pts, 7 developed CRS (4 grade 1, 3 grade 2), and 2 pts received tocilizumab; no pts had grade 3 or 4CRS... CD20 CAR-T therapy (MB-106) for BTKi-refractory WM/LPL shows high efficacy and favorable safety with nograde 3-4 CRS and no grade 2 or higher ICANS. MB-106 has received orphan drug designation by the US FDAfor WM, and a multicenter registrational phase 2 study is currently active in the US for WM. Response andtoxicity data for the full cohort from this single institution study will be updated during the presentation."

Clinical • IO biomarker • Anemia • Follicular Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia • Waldenstrom Macroglobulinemia • B2M

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy (Fortress Biotech Press Release) - P1/2 | N=287 | NCT05360238 | Sponsor: Mustang Bio | "Mustang Bio, Inc...announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T-cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia ('WM'), a rare form of blood cancer....Overall, 90% (9/10) of the patients treated with MB-106 responded to treatment, including 3 complete responses, 2 very good partial responses and 4 partial responses. In addition, 1 patient experienced stable disease. One of the patients who achieved a complete response has remained in remission for 31 months, with an immunoglobulin M (IgM) level that decreased rapidly to the normal range after treatment with MB-106 and has remained normal since."

P1/2 data • Hematological Malignancies • Oncology • Waldenstrom Macroglobulinemia

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (clinicaltrials.gov) - P1/2 | N=53 | Active, not recruiting | Sponsor: Fred Hutchinson Cancer Center | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2024 ➔ Mar 2024

Enrollment closed • Trial primary completion date • Chronic Lymphocytic Leukemia • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia • BCL2 • CTCs

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases (GlobeNewswire) - "Mustang Bio, Inc...today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center...Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases...'We believe an investigator-sponsored clinical trial is the fastest and most cost-effective way to embark on this program and aim to enroll the first patient in a Phase 1 trial in the fourth quarter of this year to demonstrate clinical proof-of-concept.'"

Pipeline update • Immunology

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) - "MB-106 (CD20-targeted CAR T-cell therapy):...We plan to move ahead with the first ever registrational CAR-T trial focused on relapsed or refractory Waldenstrom macroglobulinemia ('WM')....We expect to treat the first patient in the second half of 2024, which could enable topline results in the second half of 2026. In order to facilitate interactions with the FDA throughout this process, we anticipate requesting Regenerative Medicine Advanced Therapy (‘RMAT’) designation for indolent lymphoma - which includes WM - from the FDA in the first half of 2024."

FDA event • New trial • Indolent Lymphoma • Waldenstrom Macroglobulinemia

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - P1/2 | N=287 | NCT05360238 | Sponsor: Mustang Bio | "All patients responded clinically to treatment with MB-106 (n=9); 100% overall response rate for patients with follicular lymphoma ('FL') and Waldenstrom macroglobulinemia ('WM')...Complete responses observed in patients previously treated with CD19-targeted CAR T-cell therapy....we anticipate finalizing a recommended Phase 2 dose level in early 2024 and moving ahead with the first ever registrational CAR-T trial focused on relapsed or refractory WM. As we plan for an End-of-Phase 1 meeting with the FDA in the first half of 2024 to solicit approval for the design of this trial...Following that meeting, we anticipate initiating a trial enrolling 58 patients across 20 sites in North America, with top-line data expected as early as mid-2026."

FDA event • New P2 trial • P1 data • P2 data • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (Mustang Bio) - "...Mustang continued to make meaningful progress in the development of our lead clinical candidate MB-106...the End-of-Phase 1 meeting with the FDA expected in the first quarter of 2024, Mustang anticipates recommending dose level 2 as the Phase 2 dose for indolent lymphoma. Mustang further anticipates that results from the Phase 1 indolent lymphoma arm of the multicenter trial will support an accelerated Phase 2 registration strategy for WM, with the first pivotal Phase 2 WM patient to be treated potentially in mid-2024. Additionally, we plan to initiate a pivotal Phase 2 clinical trial in at least one additional B-cell malignancy in 2025."

FDA event • New P2 trial • Diffuse Large B Cell Lymphoma • Indolent Lymphoma • Waldenstrom Macroglobulinemia

Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (Fortress Biotech Press Release) - "We are also anticipating the PDUFA goal date of January 3, 2024, for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma ('cSCC'); We also expect to continue to advance our early-to-mid-clinical-stage candidates, some of which may begin pivotal trials during the next twelve to eighteen months, including: MB-106 – CD20-targeted CAR-T cell therapy for hematologic malignancies; MB-109 – IL13Rα2-targeted CAR-T cell therapy combined with HSV-1 oncolytic virus for recurrent glioblastoma and high-grade astrocytomas"

New trial • PDUFA date • Anaplastic Astrocytoma • Glioblastoma • Hematological Malignancies • Squamous Cell Skin Cancer

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - P1/2 | N=287 | NCT05360238 | Sponsor: Mustang Bio | "The abstract posted today on the ASH Annual Meeting website reported on four patients who received MB-106 at dose level 1 ('DL1'), 3.3×106 cells/kg: two patients with follicular lymphoma ('FL') who achieved complete response as demonstrated by both PET-CT and bone marrow biopsy, one patient with Waldenstrom macroglobulinemia ('WM') who achieved a very good partial response ('VGPR'), and one patient with transfusion-dependent hairy cell leukemia variant ('HCL-v') who continued to have stable disease with decreased bone marrow disease and who achieved complete transfusion independence which is ongoing at 6 months. All patients displayed MB-106 expansion, with peak levels between 7-14 days post-infusion, and CAR-T cell persistence is ongoing at 6 months."

P1/2 data • Chronic Lymphocytic Leukemia • Hairy Cell Leukemia • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy (GlobeNewswire) - P1/2 | N=287 | NCT05360238 | Sponsor: Mustang Bio | "Mustang Bio, Inc...announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106...demonstrating clinical responses as well as safety and efficacy consistent with the ongoing Phase 1/2 clinical trial taking place at Fred Hutchinson Cancer Center ('Fred Hutch')....The multicenter study data show clinical responses in four of four patients with relapsed or refractory indolent NHL at the starting dose of 3.3 x 106 CAR-T cells/kg, a dose comparable to that employed for the majority of the indolent lymphoma patients in the Fred Hutch trial. The multicenter data also show persistence of CAR-T cells at 6+ months and favorable safety data with only Grade 1 cytokine release syndrome ('CRS') reported to date."

P1/2 data • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (Fortress Biotech Press Release) - "...Mustang Bio’s multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 continues to accrue, and Mustang Bio anticipates escalation to the final dose level in the Phase 1 indolent lymphoma arm in the third quarter of this year....The first pivotal Phase 2 patient with WM to be treated potentially in the first quarter of 2024. Mustang Bio plans to report initial safety and efficacy data from the multicenter trial shortly, with additional safety and efficacy data from the trial expected in the fourth quarter. Finally, Mustang Bio expects to initiate a pivotal phase 2 trial in at least one additional B-cell malignancy later in 2024."

New P2 trial • P1/2 data • Trial status • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire) - "Mustang Bio, Inc...today announced that, on July 28, 2023, it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc....closed the transaction under the terms of the amended asset purchase agreement...Per the terms of the amended agreement, at closing, uBriGene acquired all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies for upfront consideration of $6 million in cash....At closing, Mustang and uBriGene also entered into a manufacturing services agreement, under which Mustang contracted uBriGene to manufacture Mustang’s lead product candidates. This includes the manufacturing of MB-106..."

Licensing / partnership • M&A • Brain Cancer • Chronic Lymphocytic Leukemia • CNS Tumor • Glioblastoma • Glioma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

MB-106 Generates Responses in BTK Inhibitor–Refractory Waldenström Macroglobulinemia (OncLive) - P1/2 | N=50 | NCT03277729 | "The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia (WM) who were refractory to a BTK inhibitor, according to data from a single-center phase 1/2 trial...presented at the 2023 EHA Congress....Findings showed that evaluable patients (n = 6) experienced an overall response rate of 83%, including a complete response rate of 33%, a very good partial response rate of 16.7%, a partial response rate of 16.7%, and a minor response rate of 16.7%. The lone non-responder had stable disease....Regarding safety, 5 patients experienced cytokine release syndrome (CRS), including 2 patients who had grade 1 CRS and 3 patients with grade 2 CRS."

Cytokine release syndrome • P1/2 data • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY (EHA 2023) - "Lymphodepletion (LD) consists of cyclophosphamide + fludarabine...All 4 pts had BTKi refractory disease (2 ibrutinib, 1 acalabrutinib, 1 zanubrutinib)...One pt received bridging therapy with bendamustine after leukapheresis and before CAR-T infusion (3 DL3 and 1 DL2)... Early results of CD20 CAR-T therapy with MB-106 for BTKi-refractory WM/LPL suggest high efficacy and favorablesafety profile with no grade 3/4 CRS and no grade 2/3/4 ICANS. MB-106 has received orphan drug designation by the US FDA for WM, and a multicenter study is currently active in the US for WM and other B-NHLs. Enrollment also continues in this single institution study, and the results will be updated during the presentation."

Clinical • IO biomarker • Anemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia • Waldenstrom Macroglobulinemia • B2M • CXCR4 • MYD88

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) - P1/2 | N=287 | NCT05360238 | Sponsor: Mustang Bio | "Mustang Bio...announced that final data from the follicular lymphoma ('FL') cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response ('ORR') and complete response ('CR') rates and CAR T persistence in FL patients....High-risk features included patients with progression of disease within 24 months of first-line chemoimmunotherapy (POD24) (n=15; 75%), history of histologic transformation (n=4, 20%), prior treatment with a CD19 target CAR T (n=1, 5%). ORR was 95% (19/20), and CR rate was 80% (16/20). Patients who received higher dose levels (3.3 x 106 and 1.0 x 107 cells/kg) had an ORR of 100% and a CR rate of 91%."

P1/2 data • Follicular Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 CAR-T (MB-106) FOR OUTPATIENT TREATMENT OF FOLLICULAR LYMPHOMA (FL)—RESULTS OF A SINGLE-INSTITUTION TRIAL (ICML 2023) - "Treatment with MB-106, a 3rd-generation CD20 targeting CAR-T, resulted in high ORR and CR rates and CAR-T persistence in FL pts and was associated with a favorable safety profile with no occurrence of Gr 3 or Gr 4 CRS and no ICANS of any grade. A multicenter trial for treatment of B-cell malignancies including FL is ongoing in the US."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) - P1/2 | N=287 | NCT05360238 | Sponsor: Mustang Bio | "Mustang Bio, Inc...announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia ('WM'), a rare form of blood cancer....Overall, 83% (5/6) of the patients treated with MB-106 responded to treatment, including 2 complete responses, 1 very good partial response, 1 partial response, and 1 minor response. In addition, 1 patient experienced stable disease. One of the patients who achieved a complete response has remained in remission for 22 months, with an immunoglobulin M (IgM) level that decreased rapidly to the normal range after treatment with MB-106 and has remained normal since."

P1/2 data • Hematological Malignancies • Oncology • Waldenstrom Macroglobulinemia

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates (GlobeNewswire) - "Mustang Bio, Inc...today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. ('uBriGene')...a leading cell and gene therapy contract development and manufacturing organization ('CDMO'), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene....Under the terms of an asset purchase agreement between Mustang and uBriGene, uBriGene will acquire Mustang’s state-of-the-art clinical- and commercial-scale cell and gene therapy manufacturing facility in Worcester, Massachusetts, for a total consideration of $11 million."

Licensing / partnership • Anaplastic Astrocytoma • Brain Cancer • Chronic Lymphocytic Leukemia • CNS Tumor • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Glioblastoma • Glioma • Hairy Cell Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Solid Tumor • Waldenstrom Macroglobulinemia

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) - "Phase 1/2 data from the Fred Hutch clinical trial on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-NHL and CLL, will be presented at the European Hematology Association Hybrid Congress ('EHA2023') taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma ('ICML') taking place June 13-17, 2023, in Lugano, Switzerland. Data from the Waldenstrom macroglobulinemia cohort were selected for poster presentation at EHA2023 and outpatient treatment of follicular lymphoma was selected for oral presentation at ICML."

P1/2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) - "...Mustang’s multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 continues to accrue, and Mustang anticipates escalation to the final dose level in the Phase 1 indolent lymphoma arm in the third quarter of this year....In the second quarter of this year, Mustang plans to report safety and efficacy data from the indolent lymphoma arm."

P1/2 data • Trial status • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia

High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL (TCT-ASTCT-CIBMTR 2022) - P1/2 | "Lymphodepletion (LD) consists of cyclophosphamide (Cy) + fludarabine (Flu). Treatment with MB-106 shows a favorable safety profile with no Gr 3-4 CRS or ICANS. In addition, we observed a high rate of ORR and CR with ongoing CRs and high rate of CAR-T persistence."

Clinical • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Lymphoma • Neuralgia • Non-Hodgkin’s Lymphoma • Oncology • Pain • CD19

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) - "...'We expect to disclose additional data from...clinical trial conducted by our collaborators at Fred Hutchinson Cancer Center...at medical meetings in the second quarter. In parallel, Mustang’s multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 continues to accrue, and we anticipate escalation to the final dose level in the Phase 1 indolent lymphoma arm in the second quarter....We expect that results from this arm will support an accelerated Phase 2 registration strategy for WM, with the first pivotal Phase 2 WM patient potentially to be treated in the first quarter of 2024. In 2023, we plan to report safety and efficacy data from the indolent lymphoma arm at medical meetings in the second quarter, with disclosure of updated data expected in the fourth quarter'."

P1/2 data • Trial status • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia